December 21, 2018

Welcome to RLS Global’s newsletter

Issue 3, 2018

The run-up to Christmas and New Year is always a time for reflection and tying up loose ends. 2018 has included a sharp focus on ensuring that ChloraSolv is granted CE approval. We announced in our Q3 report that RLS has responded to the questions from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA), and that the process is running to plan. However, this is now in the hands of the MHRA, making it hard to tell when the final decision will be made.

At the time of writing, we are working hard to draw up a future launch plan for ChloraSolv. Our enthusiastic team is looking forward to presenting our unique product to the European market in 2019. It is incredibly satisfying to know that we will soon have an effective debridement method on the market that can help a large group of patients who experience enormous suffering on a daily basis.

I would like to take this opportunity to thank you, and to wish you all a Merry Christmas and a Happy New Year. 2019 will be an exciting year, in which we embark on our commercialization journey for ChloraSolv. Alongside this, we will continue to commercialize our dental portfolio together with our international partners Straumann and REGEDENT.

Karin Fischer, CEO RLS Global

Effective wound debridement is important in order to encourage good healing

Today, the definition of wound debridement is firmly established. It is the mechanical removal of dead, damaged or infected tissue in order to improve the healing potential of the remaining healthy tissue. Effective, gentle wound debridement is essential for successful healing.

However, the actual debridement process can be carried out in a number of different ways. One of the challenges when estimating the market for wound debridement is that there are several different products with different properties and action mechanisms. There is a real need for effective new methods in order to offer gentle yet effective debridement and cleaning of wounds that do not heal easily.

ChloraSolv is a unique gel intended for debriding and cleaning wounds, and one of its components is antimicrobial sodium hypochlorite. ChloraSolv aims to facilitate the removal of necrotic tissue and biofilm while preserving healthy tissue, thus assisting natural wound healing. The devitalized necrotic tissue is easy to remove using a blunt instrument, offering an alternative to more aggressive methods such as surgical debridement. The product is ideal for use by care staff working in primary care and home care, where most wound dressing is carried out.

Since we have many patients with chronic wounds, there is great potential within the debridement market in many countries around the world. In 2017, the global market value was USD 745 million. Industry experts believe that this figure will be closer to USD 910 million by 2022. This assumption is based on annual growth in the number of diabetes patients of around 4%.

Around 60% of diabetic foot ulcers and 50% of venous leg ulcers are chronic wounds that do not heal. These wounds require some form of debridement to assist healing. Science shows that it is important to deal with biofilms and to create an antibacterial environment in order to provide the best possible conditions for the wound and its healing.

Source: Wound Debridement Products, BioMedGPS – SmartTRAK (2018)

Based on the results from RLS Global’s first study (the Dolores study, 2016), which showed improved results in the control group for diabetic ulcers, RLS has now initiated a new clinical study that includes around 60 patients. The aim is to demonstrate and document ChloraSolv’s effect early in the wound healing phase where debridement is extremely important for a positive effect on healing.


Did you know…

… around 400 million people worldwide have diabetes, and almost 200 million people have diabetes without knowing about it. (Source: Prevention and management of foot problems in diabetes, 2017)

… according to the Swedish Diabetes Association, around 500,000 Swedes have diabetes. (Source: The Swedish Diabetes Association, 2018)

… the USA and Mexico top the list of countries with the most diabetes patients. It is estimated that around two percent of the USA’s population suffers from chronic wounds linked to diabetes. (Source: Prevention and management of foot problems in diabetes, 2017)

… a lower leg amputation is carried out on a diabetes patient somewhere in the world every 30 seconds. (Source: IWGDF, International Working Group on the Diabetic Foot, 2015)


Last but not least, keep an eye out for the launch of RLS Global’s new website in January 2019. As we are attracting more and more international interest, the website will be launched in English. We aim to establish an interesting communication platform for our products within the individual indication areas aimed at all our target groups.


Merry Christmas


Happy New Year


RLS Global